ANDA 210855, held by Cipla. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 210855 (Sodium Nitroprusside), held by Cipla, was first approved by FDA on Jul 16, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 16, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Nitroprusside25MG/ML ยท injectable;injection | Sodium Nitroprusside | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters